通过PSMA PET/CT识别前列腺癌患者的偶然性脑肿瘤
PURPOSE: Brain metastases are rare in patients with prostate cancer and portend poor outcome. Prostate-specific membrane antigen positron emission tomography (PSMA PET)/CT scans including the brain have identified incidental tumors.…
要点
- 脑实质转移发生率为0.36%,脑膜瘤为0.58%,硬脑膜转移为0.14%。
- 57%的脑实质转移患者检出时无同时性颅外病变。
核心结论
- 前列腺癌脑转移罕见,尤其在没有广泛转移性疾病的情况下;然而,偶然检测到的PSMA摄取脑部病灶可能代表先前未知的前列腺癌转移,即使病变较小且无全身性疾病。
研究设计与样本
- 回顾性查询机构数据库,纳入2018年1月至2022年12月在一家NCI指定综合癌症中心接受68Ga-PSMA-11或18F-DCFPyL PET/CT成像的患者,复习影像报告和临床病程以识别脑部病变并描述临床和病理特征。
主要发现
- 识别44个脑部病变,包括33个PSMA avid病变:10个脑实质转移(30%)、4个硬脑膜转移(12%)、16个脑膜瘤(48%)、2个垂体大腺瘤(6%)和1个表皮包涵囊肿(3%),发生率分别为0.36、0.14、0.58、0.07和0.04。
- 脑实质转移的平均直径为1.99 cm(95%CI:1.25-2.73),平均SUVmax为4.49(95%CI:2.41-6.57)。
- 在检出脑实质转移时,57%的患者无同时性颅外病变,14%仅有局限性前列腺疾病,29%有颅外转移。
- 8例脑实质转移患者中有7例在中位8.8个月随访时仍存活。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Brain metastases are rare in patients with prostate cancer and portend poor outcome. Prostate-specific membrane antigen positron emission tomography (PSMA PET)/CT scans including the brain have identified incidental tumors. We sought to identify the incidental brain tumor detection rate of PSMA PET/CT performed at initial diagnosis or in the setting of biochemical recurrence. METHODS: An institutional database was queried for patients who underwent 68Ga-PSMA-11 or 18F-DCFPyL (18F-piflufolastat) PET/CT imaging at an NCI-designated Comprehensive Cancer Center from 1/2018 to 12/2022. Imaging reports and clinical courses were reviewed to identify brain lesions and describe clinical and pathologic features. RESULTS: Two-thousand seven hundred and sixty-three patients underwent 3363 PSMA PET/CT scans in the absence of neurologic symptoms. Forty-four brain lesions were identified, including 33 PSMA-avid lesions: 10 intraparenchymal metastases (30%), 4 dural-based metastases (12%), 16 meningiomas (48%), 2 pituitary macroadenomas (6%), and 1 epidermal inclusion cyst (3%) (incidences of 0.36, 0.14, 0.58, 0.07, and 0.04%). The mean parenchymal metastasis diameter and mean SUVmax were 1.99 cm (95%CI:1.25-2.73) and 4.49 (95%CI:2.41-6.57), respectively. At the time of parenchymal brain metastasis detection, 57% of patients had no concurrent extracranial disease, 14% had localized prostate disease only, and 29% had extracranial metastases. Seven of 8 patients with parenchymal brain metastases remain alive at a median 8.8 months follow-up. CONCLUSION: Prostate cancer brain metastases are rare, especially in the absence of widespread metastatic disease. Nevertheless, incidentally detected brain foci of PSMA uptake may represent previously unknown prostate cancer metastases, even in small lesions and in the absence of systemic disease.
引用
- McLaughlin LA, Yildirim O, Rosenblum MK, et al. Identification of incidental brain tumors in prostate cancer patients via PSMA PET/CT. J Neurooncol. 2023. PMID: 37247180. doi:10.1007/s11060-023-04355-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。